Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
Overview of Exosomes01:36

Overview of Exosomes

2.9K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.9K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.1K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.1K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.3K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.3K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying the Electrical Excitation Level of Quantum Dots for Mitigating Electroluminescent Efficiency Roll-Off.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Surface-ligand-triggered synthetic control of defects in nanocrystals toward high-efficiency blue electroluminescence.

Innovation (Cambridge (Mass.))·2026
Same author

Differential Coordination Chemistry with Hydrogen Peroxide: A Pathway Toward Selective Separation of Tungsten from Molybdenum.

Materials (Basel, Switzerland)·2026
Same author

The role of pterostilbene in alleviating inflammatory response and pyroptosis in myocardial ischemia-reperfusion by inhibiting the cGAS-STING pathway.

Cytotechnology·2026
Same author

Spatial heterogeneity of malignant molecular markers in glioma revealed by stereotactic biopsy.

Discover oncology·2026
Same author

Consolidation and surface protection of granite using modified polysiloxane oligomers for cultural heritage restoration.

Scientific reports·2026

Related Experiment Video

Updated: Oct 11, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.4K

Hyperleukocytic Acute Leukemia Circulating Exosomes Regulate HSCs and BM-MSCs.

Yanmei Yang1, Haiping He1, Jigang He2

  • 1Hematology Department, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.

Journal of Healthcare Engineering
|November 29, 2021
PubMed
Summary

Hyperleukocytic acute leukemia (HLAL) exosomes deliver miR-125b to stem cells, inhibiting normal blood formation. This microRNA targets BAK1, disrupting hematopoietic stem cell differentiation and bone marrow support functions.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

11.9K

Related Experiment Videos

Last Updated: Oct 11, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.4K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging
10:03

Bioengineering of Humanized Bone Marrow Microenvironments in Mouse and Their Visualization by Live Imaging

Published on: August 1, 2017

11.9K

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • Hyperleukocytic acute leukemia (HLAL) is associated with circulating exosomes that can affect normal hematopoietic processes.
  • Exosomes derived from HLAL patients may contain specific microRNAs that influence hematopoietic stem cells (HSCs) and bone marrow mesenchymal stem cells (BM-MSCs).

Purpose of the Study:

  • To investigate the role of miR-125b, carried by HLAL-derived exosomes, in regulating the hematopoietic function of HSCs and BM-MSCs.
  • To elucidate the molecular mechanism by which HLAL exosomes impact hematopoiesis, focusing on miR-125b and its target BAK1.

Main Methods:

  • Isolation of exosomes from peripheral blood of HLAL patients and healthy volunteers.
  • Co-culture of exosomes with HSCs and BM-MSCs, followed by measurement of miR-125b levels.
  • Intervention using miR-125b inhibitors/mimics and si-BAK1 to assess effects on miR-125b expression, colony-forming unit (CFU) potential, and expression of hematopoietic-related genes (e.g., CSF2, CXCL12, SCF).
  • Evaluation of the targeting relationship between miR-125b and BAK1.

Main Results:

  • miR-125b was significantly upregulated in exosomes derived from HLAL patients.
  • HLAL exosomes increased miR-125b levels in HSCs and BM-MSCs, leading to reduced CFU and altered expression of key hematopoietic factors (e.g., α-globulin, γ-globulin, CSF2, CXCL12, SCF).
  • HLAL-derived miR-125b was confirmed to target and regulate BAK1, and its effects on hematopoiesis were reversed by miR-125b mimics and si-BAK1 treatment.

Conclusions:

  • HLAL-derived exosomes carrying miR-125b actively inhibit hematopoietic stem cell differentiation and the supportive function of bone marrow mesenchymal stem cells.
  • The inhibitory mechanism involves the targeting of BAK1 by miR-125b, disrupting normal hematopoietic processes in HLAL.
  • These findings highlight a novel pathway through which HLAL impacts hematopoiesis, offering potential therapeutic targets.